Mupirocin
- Atc Codes:D06AX09#R01AX06
- CAS Codes:115074-43-6#104486-81-9
- PHARMGKB ID:115074-43-6#104486-81-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Bactroban; Belgium: Bactroban; Bulgaria: Bactroban; Cyprus: Bactroban; Czech Republic: Bactroban; Denmark: Bactroban; Finland: Bactroban; France: Bactroban, Mupiderm; Germany: Bactroban, Infectopyoderm, Turixin; Greece: Bactroban; Hungary: Bactroban; Ireland: Bactroban; Italy: Bactroban, Mupiskin; Latvia: Bactroban; Luxembourg: Bactroban; Malta: Bactroban; Netherlands: Bactroban; Poland: Bactroban, Mupirox; Portugal: Bactroban; Slovakia: Bactroban; Slovenia: Betrion; Spain: Bactrobán, Plasimine; Sweden: Bactroban; UK: Bactroban.
North America
Canada: Bactroban, Mupirocin; USA: Bactroban, Centany, Mupirocin.
Latin America
Argentina: Bactrobán, Dimsa, Mupax, Mupirox, Paldar, Vidox; Brazil: Bacrocin, Bactocin-Bunker, Bactroban, Bactroneo, Mupirocina, Supirocin; Mexico: Bacskin, Bactrobán, Sinpebac.
Asia
Japan: Bactroban.
Drug combinations
Chemistry
Mupirocin Calcium: C~52~H~86~CaO~18~ 2H~2~O. Mw: 1075.34. (1) Nonanoic acid, 9-[[3-methyl-1-oxo-4-[tetrahydro-3,4-dihydroxy-5-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-2H-pyran-2-yl]-2-butenyl]oxy]-, calcium salt (2:1), dihydrate, [2S-[2α(E),3β,4β,5α[2R*,3R*(1R*,2R*)]]]-; (2)(αE,2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate. CAS-115074-43-6; CAS-104486-81-9 (anhydrous)(1994).
Pharmacologic Category
Skin and Mucous Membrane Agents; Antibacterials. Topical Antibiotic. (ATC-Code: D06AX09; R01AX06).
Mechanism of action
Binds to bacterial isoleucyl transfer-RNA synthetase resulting in inhibition of protein synthesis.
Therapeutic use
Eradication of nasal colonization with methicillin-resistant Staphylococus aureus (MRSA) in adult patients and healthcare workers (intranasal use). Treatment of impetigo or secondary infected traumatic skin lesions due to S. aureus and S. pyogenes (topical use).
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. There are no adequate, well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.
Unlabeled use
Surgical prophylaxis to prevent wound infections (intranasal use).
Contraindications
Hypersensitivity to mupirocin or any component of the formulation.
Warnings and precautions
Irritation might occur. Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment. Potentially toxic amounts of polyethylene glycol contained in some topical products may be absorbed percutaneously in extensive burns or open wounds. For external use only. Not for treatment of pressure sores.